Pluriomics Overview

  • Year Founded
  • 2010

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 21

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Pluriomics General Information

Description

Developer of fully functional, human iPSC-derived cardiomyocytes designed for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening. The company's fully functional human iPSC-derived cardiomyocytes are manufactured using a well-defined, serum-free medium that enhances the maturation and function of the cells, along with combining with innovative technologies, in order to develop in-house cell-based assays with the objective of improving drug safety and efficacy screening, thereby enabling medical practitioners to improve decision-making, reduce attrition rates and provide an alternative for animal testing.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Biopartner building 3
  • Galileiweg 8
  • 2333 BD Leiden
  • Netherlands
Primary Industry
Other Pharmaceuticals and Biotechnology
Acquirer
Corporate Office
  • Biopartner building 3
  • Galileiweg 8
  • 2333 BD Leiden
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pluriomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 18-Sep-2017 Completed Startup
6. Later Stage VC 17-Jan-2017 Completed Startup
5. Grant 20-Jun-2016 Completed Startup
4. Grant 15-Mar-2016 Completed Startup
3. Early Stage VC (Series A) 15-Oct-2014 Completed Startup
2. Accelerator/Incubator 01-Jan-2009 Completed Startup
1. University Spin-Out Completed Startup
To view Pluriomics’s complete valuation and funding history, request access »

Pluriomics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of fully functional, human iPSC-derived cardiomyocytes designed for efficient and reliable safety pharmacology
Other Pharmaceuticals and Biotechnology
Leiden, Netherlands
21 As of 2019

Newcastle upon Tyne, United Kingdom
 

Raleigh, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pluriomics Competitors (17)

One of Pluriomics’s 17 competitors is Alcyomics, a Formerly VC-backed company based in Newcastle upon Tyne, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Alcyomics Formerly VC-backed Newcastle upon Tyne, United Kingdom
Parexel International Private Equity-Backed Raleigh, NC
FUJIFILM Cellular Dynamics Formerly VC-backed Madison, WI
Charles River Laboratories International Formerly PE-Backed Wilmington, MA
bit.bio Venture Capital-Backed Cambridge, United Kingdom
You’re viewing 5 of 17 competitors. Get the full list »

Pluriomics Patents

Pluriomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2017164746-A1 In vivo method for differentiating human pluripotent stem cells into atrial cardiomyocytes Inactive 25-Mar-2016
WO-2017039445-A1 An in vitro method of differentiating a human pluripotent stem cell population into a cardiomyocyte cell population Inactive 01-Sep-2015
WO-2016133392-A1 Assays for measuring cardiotoxicity Inactive 20-Feb-2015
WO-2015187023-A1 Cardiomyocyte maturation Inactive 06-Jun-2014
WO-2014200339-A1 Culture medium compositions for maturating cardiomyocytes derived from pluripotent mammalian stem cells Inactive 11-Jun-2013 C12N5/0657
To view Pluriomics’s complete patent history, request access »

Pluriomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pluriomics Former Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Carbon ( Belgium ) Venture Capital Minority
Horizon 2020 Government
InnovationQuarter Venture Capital Minority
LifeSciences@Work Accelerator/Incubator
Société Fédérale de Participations et d'Investissement Holding Company Minority
You’re viewing 5 of 7 investors. Get the full list »

Pluriomics FAQs

  • When was Pluriomics founded?

    Pluriomics was founded in 2010.

  • Where is Pluriomics headquartered?

    Pluriomics is headquartered in Leiden, Netherlands.

  • What is the size of Pluriomics?

    Pluriomics has 21 total employees.

  • What industry is Pluriomics in?

    Pluriomics’s primary industry is Other Pharmaceuticals and Biotechnology.

  • Is Pluriomics a private or public company?

    Pluriomics is a Private company.

  • What is Pluriomics’s current revenue?

    The current revenue for Pluriomics is .

  • How much funding has Pluriomics raised over time?

    Pluriomics has raised $8.35M.

  • Who are Pluriomics’s investors?

    Carbon ( Belgium ), Horizon 2020, InnovationQuarter, LifeSciences@Work, and Société Fédérale de Participations et d'Investissement are 5 of 7 investors who have invested in Pluriomics.

  • Who are Pluriomics’s competitors?

    Alcyomics, Parexel International, FUJIFILM Cellular Dynamics, Charles River Laboratories International, and bit.bio are some of the 17 competitors of Pluriomics.

  • When was Pluriomics acquired?

    Pluriomics was acquired on 18-Sep-2017.

  • Who acquired Pluriomics?

    Pluriomics was acquired by Ncardia.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process